Clinical trials
Relapse clinical trials
Below are recruiting relapse clinical trials, each written for real people, not researchers. We’re tracking 903 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04836507RecruitingPhase 1/Phase 2
Study of a lab-made cell therapy for lymphoma and leukemia
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT07478848RecruitingPhase 1
Radiation, Vancomycin, and CAR-T for B-cell lymphoma
This trial tests whether giving radiation and an oral antibiotic (vancomycin) before CAR-T therapy helps treat B-cell lymphoma more effectively. It is for people who are already scheduled to receive CAR-T treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07638553RecruitingPhase 3
Psilocybin to prevent alcohol relapse with depression
This study tests whether psilocybin (a psychedelic compound) can help people with severe alcohol use disorder stay sober longer, especially if they also have depression. Participants receive guided psilocybin sessions alongside counseling to reduce the risk of returning to heavy drinking.
BayonneAges 18 years+ - NCT07353216Recruiting
Testing ofatumumab for relapsing multiple sclerosis
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Guangzhou, GuangdongAges 18 years+ - NCT07355387Recruiting
Home-based balance training for multiple sclerosis
This study tests a 12-week home-based balance training program for people with multiple sclerosis. Sessions are done online with a helper present, and the goal is to improve walking and reduce fall risk.
Chicago, IllinoisAges 40–90 - NCT07356154RecruitingPhase 1/Phase 2
Study of revumenib and mezigdomide for leukemia
This trial tests two experimental drugs, revumenib and mezigdomide, for people with acute leukemia that has certain genetic changes (NPM1, KMT2A, or NUP98) and has come back or not responded to prior treatment. The goal is to see if this combination can help control the leukemia.
Duarte, CaliforniaAges 12 years+ - NCT07357519RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced osteosarcoma
This trial tests a new targeted radiation treatment (177Lu-TARGETed Osteosarcoma Therapy) for people with advanced osteosarcoma that has not responded to or has come back after prior chemotherapy. The goal is to see if this treatment can help shrink or control the cancer.
Los Angeles, CaliforniaAges 12 years+ - NCT07360977Recruiting
Broccoli supplement for Parkinson's and multiple sclerosis
This trial tests a natural compound (from broccoli sprouts) called glucoraphanin, which may help protect brain cells in people with Parkinson's disease or multiple sclerosis. It aims to see if taking this supplement can slow down or improve symptoms.
MessinaAges 1–75 - NCT07361029RecruitingPhase 1
CAR T cell therapy for adults with returning B-cell leukemia
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Riyadh, Riyadh RegionAges 18–75 - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07369492RecruitingPhase 1
Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
SuzhouAges 18 years+ - NCT07374029RecruitingPhase 1
T cell therapy with vaccine, decitabine, and venetoclax in AML
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
Boston, MassachusettsAges Any age - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT07376772Recruiting
Wearable vibration therapy for arm and hand function in multiple sclerosis
This study tests if a wearable device that gently vibrates the arm can improve hand and arm function in people with multiple sclerosis. You would use the device at home while doing daily activities.
Gainesville, FloridaAges 18–100 - NCT07377435RecruitingPhase 1
Vaccine after CAR-T therapy for multiple myeloma
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Boston, MassachusettsAges 18 years+ - NCT07377578RecruitingPhase 3
Rocbrutinib vs other BTK inhibitors for mantle cell lymphoma
This study tests a new targeted therapy called Rocbrutinib against other BTK inhibitors for people with mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see which works better and how safe they are.
Beijing, Beijing MunicipalityAges 18 years+ - NCT01804634RecruitingPhase 2
Reduced-intensity stem cell transplant for high-risk solid tumors
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
Baltimore, MarylandAges 1–50 - NCT01269853RecruitingPhase 1/Phase 2
Bevacizumab directly into brain arteries for recurrent brain tumors
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
New York, New YorkAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Birmingham, AlabamaAges 18 years+ - NCT02259556RecruitingPhase 1/Phase 2
CAR T treatment for CD30-positive lymphomas after standard therapies
This trial tests a lab-made immune cell therapy (CAR T) that targets CD30 on certain lymphoma cells. It may help people whose Hodgkin or non-Hodgkin lymphoma has come back or did not respond to usual treatments, including transplant and other medicines.
Beijing, Beijing MunicipalityAges 16–80 - NCT02917083RecruitingPhase 1
CD30 CAR T cell treatment for hard-to-treat lymphomas
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
Houston, TexasAges 12–75 - NCT02961101RecruitingPhase 1/Phase 2
Anti–PD-1 immunotherapy with or without chemo for hard-to-treat cancers
This early-phase study tests an anti–PD-1 antibody, either alone or with decitabine or chemotherapy, in people whose cancer has come back or isn’t responding to treatment. It may help your immune system attack the cancer, especially after prior therapies.
Beijing, Beijing MunicipalityAges 12–75 - NCT03196414RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed myeloma with multiple targets
This trial tests an immune therapy made from T cells to attack multiple markers on multiple myeloma cells (including CD138 and BCMA). It may help people whose myeloma has come back or resisted treatment, when there are no curative options left.
Suzhou, JiangsuAges 18–75 - NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+
Hear when a new Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapse?
- Yes. Clin2 currently lists 903 recruiting relapse studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapse trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapse trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.